PHARMACEUTICAL 2025

Monopar Therapeutics
Rank 18 of 225

Monopar Therapeutics



PHARMACEUTICAL 2025

Monopar Therapeutics

Monopar Therapeutics
Rank 18 of 225

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 189% points.The greatest weakness of Monopar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 381%, being 167% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	60,291
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	50
Other Expenses	0
Other Liabilities	5,254
Other Net Income	404
Other Revenues	171
Property and Equipment	0
Research and Development	13,006
Selling, General and Administrative Expense	3,156

Output Variable	Value in 1000 USD
Assets	60,291
Liabilities	5,254
Expenses	16,162
Revenues	171
Stockholders Equity	55,037
Net Income	-15,586
Comprehensive Net Income	-15,561
BaseVar	41,166
ECR before LimitedLiability	319%
Economic Capital Ratio	381%